Delivery Order SPE2DB24D2212-SPE2DB25FHQPD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,227.41 to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under AmerisourceBergen's larger pharmaceutical supply contract. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (90-count supply) on September 9, 2025, with a ceiling value of $3,650.59. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a non-competitive set-aside contract. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (90 count) on September 10, 2025, with a ceiling value of $7,323.42 and firm fixed pricing. This non-set-aside, competitively awarded contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $7,133.83 to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 MG tablets (90-count supply) on June 25, 2025, with completion targeted for June 26, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for MYRBETRIQ ER 50 MG tablets (quantity: 90-count supply) with a ceiling value of $3,120.05 under a firm fixed price contract. This is a non-set-aside award issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999.99 billion potential value through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $1,720.92 to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (30-count supply) on September 9, 2025, with completion targeted for September 10, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing pharmaceutical supply agreements with DLA. The medication will be delivered to the company's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $9,866.33 to AmerisourceBergen Drug Corp for MYRBETRIQ ER 25 MG tablets (90 count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This firm fixed price, non-set-aside contract represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $15,115.77 to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (90-count supply). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 30, 2025, and represents a continuation of pharmaceutical supply fulfillment under the company's existing contract vehicle with DLA. MYRBETRIQ (mirabegron) is a beta-3 agonist used in the treatment of overactive bladder, indicating this...
- The Defense Logistics Agency awarded a delivery order valued at $2,257.06 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a pharmaceutical product used primarily for treating overactive bladder. The contract was competitively awarded without a set-aside designation under a firm fixed-price arrangement, with the ultimate completion date set for June 18, 2025. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania served as the place of performance. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,746.38 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication commonly used to treat overactive bladder. The award was made on September 12, 2025, with an ultimate completion date of September 15, 2025, under a firm fixed-price contract type with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB24D2212Indefinite Delivery Contract
- SPE2DB24D2212-SPE2DB25FHQPDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $20,957.72 to AmerisourceBergen Drug Corp for the supply of MYRBETRIQ ER 50 mg tablets (90-count units). This competitive award, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical prime vendor contract enables the company to supply a broad range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare systems globally. MYRBETRIQ, a brand-name medication for overactive bladder treatment, represents one component of the extensive pharmaceutical portfolio AmerisourceBergen delivers through this strategic vehicle to serve the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.0k | 8/15/25 |